舒更葡糖钠对肾移植术患者远期预后的影响  

Effect of sugammadex on long-term prognosis in patients undergoing kidney transplantation

作　　者：吴钿生[1] 周洪彬[1] 王卓丹 黄焕森[1] Wu Diansheng;Zhou Hongbin;Wang Zhuodan;Huang Huansen(Department of Anesthesiology,Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China)

机构地区：[1]广州医科大学附属第二医院麻醉科,广州510260

出　　处：《中华麻醉学杂志》2023年第4期410-413,共4页Chinese Journal of Anesthesiology

摘　　要：目的评价舒更葡糖钠对肾移植术患者远期预后的影响。方法回顾性分析2018年1月1日至2021年10月31日本院心脏死亡器官捐献肾移植术患者临床资料,年龄18~64岁,性别不限,BMI 18~30 kg/m^(2),ASA分级Ⅲ或Ⅳ级,根据肌松拮抗剂使用情况分为:舒更葡糖钠组(S组)和对照组(C组)。记录术后1年并发症发生情况及1和3年生存和肾存活情况。结果共纳入645例患者,S组319例,C组326例。2组术后1年并发症发生率比较差异无统计学意义(P>0.05)。S组1、3年生存率分别为94.7%和92.8%,肾存活率分别为94.4%和89.4%;C组1、3年生存率分别为96.6%和94.7%,肾存活率分别为93.9%和88.6%;2组生存率和肾存活率比较差异无统计学意义(P>0.05)。结论舒更葡糖钠对肾移植术患者远期预后无明显影响。Objective To evaluate the effect of sugammadex on the long-term prognosis in the patients undergoing kidney transplantation.Methods American Society of Anesthesiologists Physical Status classificationⅢorⅣpatients of either sex,aged 18-64 yr,underwent donation after cardiac death renal transplantation from January 1,2018 to October 31,2021,were included in this study.Their clinical data were retrospectively analyzed,and then the patients were divided into 2 groups:sugammadex group(group S)and control group(group C).The complications at 1 yr after surgery and patient/graft survival at 1 and 3 yr after surgery were recorded.Results A total of 645 patients were finally enrolled in this study,with 319 patients in group S and 326 patients in group C.There was no significant difference in the incidence of postoperative complications within 1 yr after surgery between two groups(P>0.05).The overall patient survival rate at 1 and 3 yr after surgery were 94.7%and 92.8%respectively,and the death-censored graft survival at 1 and 3 yr after surgery were 94.4%and 89.4%respectively in group S.The overall patient survival rate at 1 and 3 yr after surgery were 96.6%and 94.7%respectively,and the death-censored graft survival at 1 and 3 yr after surgery were 93.9%and 88.6%respectively in group C.There was no significant difference in patient/graft survival rate between two groups(P>0.05).Conclusions Sugammadex has no obvious effect on the long-term prognosis in the patients undergoing kidney transplantation.

关 键 词：舒更葡糖 肾移植 预后 

分 类 号：R614[医药卫生—麻醉学]